• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Menlo Therapeutics changes name to VYNE Therapeutics


Menlo Therapeutics has officially changed its name to VYNE Therapeutics.

Menlo Therapeutics is now VYNE Therapeutics Inc., according to a company announcement September 2, 2020.

“Our new corporate branding, VYNE Therapeutics, reflects an evolution of our business which combines the strengths and traditions of our legacy companies ─ Menlo Therapeutics and Foamix Pharmaceuticals ─ with our ambition to build a sustainable, fully integrated pharmaceutical company in dermatology and beyond,” says David Domzalski, president and CEO.

The company’s current pipeline contains a variety of products equipped with their Molecule Stabilizing Technology (MST), including the world’s first topical minocycline foam 4% (AMZEEQ), which was approved by the U.S. Food and Drug Administration (FDA) in October 2019 for treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in adult and pediatric patients ages 9 years and older.

RELATED: Foamix and Menlo announce approval of merger

Also approved by the FDA in May 2020, a topical minocycline foam 1.5% (ZILXI) for treatment of rosacea, which became the first minocycline product approved for this indication.

“Having achieved FDA approval for our two commercial products AMZEEQ and ZILXI ─ in a period of less than eight months ─ is a testament to the value of our proprietary technology and is aligned to the symbolic meaning behind our new name ─ strength, growth, endurance, and resilience,” says Domzalski. “We are focused on growing the business, building our franchise in a way that will maximize our operational capabilities, and developing a pipeline of innovative products to address unmet needs for patients.”

MORE: FDA approves first topical minocycline for rosacea

Most recently, VYNE Therapeutics (formerly Menlo Therapeutics) finalized its merger with Foamix Pharmaceuticals Ltd. in March 2020, which is now a wholly owned subsidiary of VYNE.

More information can be found at www.vynetherapeutics.com.


Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics. (2020, September 2). Retrieved September 10, 2020, from https://vynetherapeutics.com/press-releases/menlo-therapeutics-announces-corporate-name-change-to-vyne-therapeutics/

Related Videos
© 2024 MJH Life Sciences

All rights reserved.